Calchan Overview

  • Founded
  • 2011
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Calchan General Information


Developer of novel molecules designed to focus on research and development of molecules targeting pain and inflammation. The company's molecules are used for the treatment of calcium channel blockers for neuropathic pain indications, enabling patients to be cured of neuropathic diseases in a cost-efficient way.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Warwick House Spitfire Close Ermine Business Park
  • Cambridgeshire
  • Huntingdon PE29 6XY
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Calchan Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 06-Nov-2020 0000 Completed Out of Business
2. Grant 27-Oct-2014 00.000 0000 Completed Clinical Trials - General
1. Early Stage VC (Series A) 09-Nov-2012 $10M $10M Completed Startup
To view Calchan’s complete valuation and funding history, request access »